| Business Summary | | Endorex
Corporation
is
a
development
stage,
drug
delivery
company.
The
Company's
core
drug
delivery
technology
focuses
on
oral/mucosal
delivery
of
drugs
and
vaccines
previously
delivered
only
by
injection.
The
Company's
Orasome
system
utilizes
technology
licensed
from
Massachusetts
Institute
of
Technology
to
develop
the
oral/mucosal
delivery
of
vaccines,
proteins
and
peptides.
In
1998
the
Company
formed
two
joint
ventures
with
Elan
Corporation,
plc,
one
of
the
world's
leading
drug
delivery
companies.
The
purpose
of
the
first
joint
venture,
InnoVaccines
Corporation,
is
to
research,
develop,
and
commercialize
novel
delivery
systems
for
the
human
and
veterinary
vaccine
markets.
The
second
joint
venture,
Endorex
Newco,
LTD.,
focuses
on
the
utilization
of
the
MEDIPAD
microinfusion
pump,
developed
by
Elan,
to
deliver
iron
chelators
for
the
treatment
of
a
series
of
genetic
blood
disorders
known
as
iron
overload
disorders. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Endorex
Corporation
is
a
development
stage
bio-technology
company
involved
in
oral
drug
delivery
and
cancer
therapy.
The
Company
has
developed
two
products
which
have
undergone
clinical
trials.
For
the
six
months
ended
6/30/01,
the
Company
reported
no
revenues.
Net
loss
applicable
to
Common
fell
8%
to
$3.1
million.
Lower
loss
reflects
an
overall
decrease
in
joint
venture
R&D
activities
as
the
Company
redirected
its
drug
delivery
research
focus. | More
from
Market Guide: Significant
Developments |
| | | | FY1999 Pay | |
| Kenneth Tempero, M.D., Ph.D., 60 Chairman | -- | Michael Rosen, 47 Pres,
CEO | $269K | Frank Reid, 50 VP
of Fin. and Corp. Devel. | -- | Panayiotis Constantinides, Ph.D. VP-R&D | -- | John McCracken VP-Bus.
Devel. | -- | Dollar amounts are as of 31-Dec-1999 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|